by Bioblast Editor | Oct 1, 2020 | Biosimilars updates
Lupin receives approval for biosimilar etanercept in Australia under the trade names Etera® and Rymti® in PFS presentations.
by Bioblast Editor | Sep 15, 2020 | Biosimilars updates
Merck announced Health Canada has approved Brenzys® (biosimilar etanercept) for four new indications: adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy pediatric patients ages 4 to 17 years...
by Bioblast Editor | Aug 26, 2020 | Biosimilars updates
Lupin and Mylan launch Nepexto® (biosimilar etanercept) in Germany. Nepexto® is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, severe axial spondyloarthritis and plaque psoriasis.
by Bioblast Editor | Jul 28, 2020 | Biosimilars updates
Pfizer releases its Q2 FY20 financial results. Pfizer reported a 16% decrease in international revenues for Enbrel® (etanercept), attributing this decrease to biosimilar competition in Europe, Japan and Brazil.
by Bioblast Editor | Jul 1, 2020 | Biosimilars updates
Sandoz responds to the US Court of Appeals judgment which upheld a ruling from the New Jersey District Court which declared the Amgen patents relating to (etanercept) valid. Sandoz stated that it will continue its efforts to make Erelzi® available in the US, and is...
